Vesedaganat: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• HIF-1 0
• YAP 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

3+ intézményből 3, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Identification of TILs-specific novel lincRNA and their functional importance in mediating immune response in renal cell carcinoma (REGULINC)

  Turun Yliopisto· Turku, Finnország· EU contribution 226 277 EUR· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-ERC

  IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)

  Universita Vita-Salute San Raffaele· Milano, Olaszország· EU contribution 1 500 000 EUR· until 2029. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  TARGETING INHERITED CANCER SYNDROMES (INCANTAR)

  Fondazione Telethon Ets· Roma, Olaszország· EU contribution 2 496 625 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-RIA

  First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma (CARE1)

  Institut Gustave Roussy· Villejuif, Franciaország· EU contribution 5 577 694 EUR· until 2028. ápr.· 14 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care (COMFORT)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Németország· EU contribution 5 906 596 EUR· until 2027. márc.· 7 countries

• European Commission (Horizon Europe) · HORIZON-EIC

  Breaking the penetration limit of microscopy – Photoswitching Optoacoustics (SWOPT)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Németország· EU contribution 3 536 935 EUR· until 2027. aug.· 5 countries

  The disease is named only in the funder's project summary, not in the title.

6 of 6 running projects, newest first. Listed amounts together: 19,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  MSD Belzutifan PAS

  NCT06554730· Merck Sharp & Dohme LLC· Frissítve: 2024. nov. 29.

  “Study is registered /active on RWD Catalogues (https://catalogues.ema.europa.eu) - Please refer to EU PAS number: EUPAS108114”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)

  2025-524160-38-00· Merck Sharp & Dohme LLC· Forrás

• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

  NCT00001238· National Cancer Institute (NCI)· Forrás

• A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

  NCT03401788· Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Forrás

• Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

  NCT07167329· José Claudio Casali da Rocha· Forrás

• MyVHL: Patient Natural History Study

  NCT03749980· Joshua Mann, MPH· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 77
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 60
• Machine Learning 71
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Molecular underpinnings of metastatic small renal masses.

  JCI Insight, 2026. szept.

• Mass Spectrometry-Based Profiling of Personalized Immunopeptidomes in Thai Renal Cell Carcinoma.

  J Proteome Res, 2026. szept.

• [Driver gene mutations predicted by pathology-foundation-model and their clinical associations in clear cell renal cell carcinoma].

  Zhonghua Bing Li Xue Za Zhi, 2026. máj.

• Integrated clinicopathological, genomic, and immunophenotypic landscape of renal tubulocystic oncocytoma.

  Front Immunol, 2026. ápr.

• Subtyping atypical eosinophilic renal cell tumours through integrated morphological, immunohistochemical, and mutational characters.

  BMC Cancer, 2026. márc.

• Integrated genetic and clinical investigation of autosomal dominant hereditary uterine leiomyomas: genotype-phenotype correlation in a pakistani family.

  Mol Biol Rep, 2026. febr.

• Hemangioblastoma of the Kidney-A Comprehensive Clinical, Pathological, and Genetic Analysis of Four Cases.

  APMIS, 2026. jan.

• Assessing the Mutational Consequences of Chronic Arsenic Exposure Using Patient-Derived Tumor Samples and In Vitro Systems.

  Environ Mol Mutagen, 2026. jan.

• Integrating whole-exome sequencing and scRNA-seq reveal the characteristic in one clear cell renal cell carcinoma sample arising in the setting of VHL disease.

  Sci Rep, 2025. dec.

• Conventional FLCN-mutated tumor: a retrospective study of 5 cases with emphasis on diagnostic challenges.

  Hum Pathol, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.